Peter Graf
Investment Manager @ BayBG Venture Capital
Peter Graf is an investment manager at BayBG.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Peter Graf invests in
Stages Peter Graf invests in
Countries Peter Graf invests in
Investment Focus
Industry
- Health Care 3 (75%)
- Medical 2 (50%)
- SaaS 1 (25%)
- Dental 1 (25%)
- Software 1 (25%)
Stage
- Venture - Series Unknown 2 (50%)
- Seed 1 (25%)
- Series B 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AlfaDocs
|
AlfaDocs is the new generation of doctor practice management systems. Our mission is to make doctor practice management more efficient and intelligent, with the vision to improve the world of health care.We are connecting patients and doctors in a whole new way, with a healthcare platform that changes the everyday life in and around doctor'spractices.We are to accomplish our vision by offering service-oriented technological solutions: digitalization, centralization, automation, and integration. That is why we developed AlfaDocs, the first real Practice & Patient-Relationship Management cloud-based platform.Since launch about three years ago on the Italian market, our Munich-based team has quickly grown the business to a solid customer base and raised several investments. We have become one of the best solutions for practice management in Italy and we're looking to take the company international, entering several other markets, to finally become the #1 European solution for Practice & Patient-Relationship Management.In Italy, AlfaDocs is already the clear market leader in the area of cloud-based practice management systems (PMS) for dentists. | $2.1M / Venture - Series Unknown / Feb 10, 2023 | |
Munevo
|
Munevo empowers people with disabilities by using smart and innovative technology. | $3M / Venture - Series Unknown / Oct 21, 2022 | |
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series B / Apr 16, 2020 | |
Plasmion
|
The only "chemoselective" sense of human kind is the sense of smell. Through this sense They are able to perceive taste, aroma, and hazardous substances, such as hydrogen sulfide. Unfortunately, this sense is evolutionarily hampered for human beings compared to animals like dogs, for instance. Also from a technological perspective thereis no sensitive and selective "electronic nose" available, yet. Therefore, thay are strive to provide a novel sensor technology based on ambient mass spectrometry which does not only improve the utilization in traditional laboratory environments, but also enables the transfer of this kind of sensor technology to industrial process control, forensics, security technology (drugs, explosives, etc.) and the medical "point of care" diagnostics. | $1.1M / Seed / Feb 16, 2019 |
Co-Investors
Bayern Kapital
2 deals together
TVM Capital Life Science
2 deals together
BayStartUP
1 deal together
be-exponential
1 deal together
About BayBG Venture Capital
Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
BayBG Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andreas Heubl
Investment Manager
|
|||
Lukas Biberacher
Senior Investment Manager Venture Capital
|
|||
Marcus Gulder
Head of Venture CapitalCapital
|
|||
|
Peter Graf
Investment Manager
|
|||
Peter Pauli
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Peter Graf invest in?
Peter Graf invests primarily in Health Care, Medical and SaaS startups, most often at Venture - Series Unknown and Seed stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Peter Graf last invest?
The most recent investment recorded for Peter Graf closed in Feb 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
